$23.99 0.0 0.0%
Last Trade - 15/02/17
| Market Cap | £n/a |
| Enterprise Value | £n/a |
| Revenue | £133.7m |
| Position in Universe | th / 6852 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 179 | 25.3 | 0.56 | 45.6 | 105.4 | 118.8 | 196.1 | 245 | -7.9% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
| Last Annual | December 31st, 2015 |
| Last Interim | September 30th, 2016 |
| Incorporated | April 12, 1991 |
| Public Since | May 20, 1994 |
| No. of Shareholders: | 288 |
| No. of Employees: | 459 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 194,200,862 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 125 Binney St, CAMBRIDGE, 02142-1123, United States |
| Web | |
| Phone | +1 617 4940400 |
| Contact | () |
| Auditors | Deloitte & Touche LLP |
As of 15/02/17, shares in ARIAD Pharmaceuticals Inc are trading at $23.99, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.
Shares in ARIAD Pharmaceuticals Inc are currently trading at $23.99 and the price has moved by 0.394k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ARIAD Pharmaceuticals Inc price has moved by 0.234k% over the past year.
Of the analysts with advisory recommendations for ARIAD Pharmaceuticals Inc, there are there are currently 1 "buy" , 7 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ARIAD Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
ARIAD Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
ARIAD Pharmaceuticals Inc does not currently pay a dividend.
ARIAD Pharmaceuticals Inc does not currently pay a dividend.
ARIAD Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in ARIAD Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in ARIAD Pharmaceuticals Inc are currently trading at $23.99, giving the company a market capitalisation of £n/a.
Here are the trading details for ARIAD Pharmaceuticals Inc:
We were not able to load our ranking data for ARIAD Pharmaceuticals Inc
We were not able to load any forecast data for ARIAD Pharmaceuticals Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ARIAD Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 91.38%. At the current price of $23.99, shares in ARIAD Pharmaceuticals Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for ARIAD Pharmaceuticals Inc.
We were unable to find the directors for ARIAD Pharmaceuticals Inc.
Here are the top five shareholders of ARIAD Pharmaceuticals Inc based on the size of their shareholding:
